Drug Profile
Amlodipine/olmesartan-medoxomil/rosuvastatin - Daewoong Pharmaceutical
Alternative Names: Amlodipine besylate/olmersartan medoxomil/rosuvastatin calcium; Amlodipine/olmesartan/rosuvastatin; DWJ1351; Olmersartan medoxomil/amlodipine besilate/rosuvastatin calcium; Olmersartan medoxomil/amlodipine besylate/rosuvastatin calcium; Olmesartan/amlodipine/rosuvastatin; OlomaxLatest Information Update: 25 Oct 2021
Price :
$50
*
At a glance
- Originator Daewoong Pharmaceutical
- Class Antihyperlipidaemics; Antihypertensives; Cardiovascular therapies; Dihydropyridines; Fluorobenzenes; Imidazoles; Pyrimidines; Small molecules; Sulfonamides; Tetrazoles
- Mechanism of Action Angiotensin type 1 receptor antagonists; Calcium channel antagonists; Cytochrome P 450 enzyme system inhibitors; HMG-CoA reductase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Hyperlipidaemia; Hypertension
Most Recent Events
- 19 Jul 2019 Daewoong Pharmaceutical completes a phase III trial in Hyperlipidaemia and Hypertension in South Korea (PO) (NCT03009487)
- 19 Jul 2019 Efficacy data from a phase III trial in Hypertension and Hyperlipidaemia released by Daewoong Pharmaceutical
- 26 Jan 2018 Daewoong Pharmaceutical completes enrolment in a phase I trial in Healthy volunteers in South Korea (NCT03753477)